ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

デオキシコール酸

Deoxycholic Acid

HCID 222528
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
83-44-3
標準SMILES
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
InChIKey
KXGVEGMKQFWNSR-LLQZFEROSA-N
分子式
C24H40O4
平均分子量
392.6 g/mol
単同位体質量
392.29265975

概要

Deoxycholic acid is a bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively. It has a role as a human blood serum metabolite. It is a C24-steroid, a dihydroxy-5beta-cholanic acid and a bile acid. It is a conjugate acid of a deoxycholate.

名称と識別子

優先名称
Deoxycholic Acid
IUPAC
(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
現地名
デオキシコール酸
英語名
Deoxycholic acid
分子式
C24H40O4
分子量
392.58

名称と別名

DEOXYCHOLIC ACID83-44-3CholerebicCholorebicCholeic acidDroxolanDegalolDesoxycholsaeureDeoxycholatic acidPyrocholSeptochol7-Deoxycholic acid
名称をさらに表示
デオキシコール酸コレイン酸デスオキシコール酸ドロキソランデソキシコール酸7-デオキシコール酸3,12-ジヒドロキシコラン酸デガロール3α,12α-ジヒドロキシ-5β-コラン-24-酸デオキシコラートデオキシコール酸, 99%(4R)-4-[(1R,3aS,3bR,5aR,7R,9aS,9bS,11S,11aR)-7,11-ジヒドロキシ-9a,11a-ジメチル-ヘキサデカヒドロ-1H-シクロペンタ[a]フェナントレン-1-イル]ペンタン酸DEOXYCHOLATEdeoxycholicDESOXYCHOLIC ACID(R)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-diMethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acidCHOLAIC ACIDDEOXYCHOLIC ACID FREE ACID SIGMAULTRANSC 8797
7alpha-Deoxycholic acid3alpha,12alpha-Dihydroxy-5beta-cholanic acidCholic acid, deoxy-3,12-Dihydroxycholanic acidATX-101Dihydroxycholanoic acidDeoxy cholic acid3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid

物性

構造計算による物性

XLogP
4.9
極性表面積
77.8 Ų
水素結合供与体数
3
水素結合受容体数
4
回転可能結合数
4
重原子数
28
形式電荷
0
複雑度
605

実験および物理化学的性質

Chemical Classes · 2 件

Bile Acids -> Quant Bile Acids

Other Classes -> Organic Acids

DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Sterol Lipids [ST] -> Bile acids and derivatives [ST04] -> C24 bile acids, alcohols, and derivatives [ST0401]
SpringerMaterials PropertiesCrystal structure
LogP · 2 件

log Kow = 3.50

3.50

Color/FormCRYSTALS FROM ALC
Solubility · 4 件

SOLUBILITY IN WATER: GREATER THAN 333 G/L @ 15 °C /NA SALT/

@ 15 °C: 0.24 G/L IN WATER, 220.7 G/L IN ALC, IN ETHER: 1.16 G/L, IN CHLOROFORM: 2.94 G/L, IN BENZENE: 0.12 G/L, IN ACETONE: 10.46 G/L, IN GLACIAL ACETIC ACID: 9.06 G/L; SOL IN SOLN OF ALKALI HYDROXIDES OR CARBONATES

water solubility = 43.6 mg/l @ 20 °C

0.0436 mg/mL

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

DecompositionWhen heated to decomposition it emits acrid smoke and irritating fumes.

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 49 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory Information · 3 件

Chemical: Cholan-24-oic acid, 3,12-dihydroxy-, (3.alpha.,5.beta.,12.alpha.)-

REACH registered substance: 3-α,12-α-dihydroxy-5-β-cholan-24-oic acid (EC: 201-478-5)

Deoxycholic acid: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Cholan-24-oic acid, 3,12-dihydroxy-, (3.alpha.,5.beta.,12.alpha.)-: Human health tier I assessment
Hazards SummaryEmergency treatment: symptomatic drug ingestion; [HSDB] An irritant; [MSDSonline]
Hazard Classes and CategoriesAcute Tox. 4 (100%)

安全と保護具

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

化学と産業

薬理情報

ATC Code · 2 件

D - Dermatologicals

QD - Dermatologicals

Bionecessity · 1 件

Normal functioning of the GI tract depends on appropriate synthesis and enterohepatic circulation of bile acids ... which are synthesized from cholesterol The primary bile acids are cholic acid and chenodeoxycholic acid. Bacterial metabolism of these primary bile acids in the colon forms secondary bile acids, of which deoxycholic acid is the principal specie. Secondary bile acids are absorbed in the colon and cycle with the primary bile acids. Cholic acid, chenodeoxycholic acid, and deoxy- cholic acid constitute 95% of the biliary bile acids.

Protein Binding98%
Mechanism of Action · 3 件

As a bile acid, deoxycholic acid emulsifies fat in the gut. Synthetically derived deoxycholic acid, when injected, stimulates a targeted breakdown of adipose cells by disrupting the cell membrane and causing adipocytolysis. This results in an inflammatory reaction and clearing of the adipose tissue remnants by macrophages. Deoxycholic acid's actions are reduced by albumin and tissue-associated proteins, therefore its effect is limited to protein-poor subcutaneous fat tissue. Protein-rich tissues like muscle and skin are unaffected by deoxycholic acid, contributing to its safety profile.

IN SOLN CONJUGATED BILE SALTS FORM MICELLES IN WHICH LIPID MATERIALS MAY BE ENTRAINED. ...ALSO PROMOTE DIGESTION OF FATS BY STIMULATING PANCREATIC SECRETION & BY ACTIVATING PANCREATIC LIPASE. ... DEOXYCHOLIC.../ACID/ PROMOTE/S/ NET EXCRETION OF NA, K, & WATER IN COLON...MAY BE...FACTORS REGULATING COLONIC ABSORPTION.

DEOXYCHOLATE ADMIN DECR ABSORPTION OF CHOLESTEROL FROM HUMAN INTESTINAL TRACT. IT APPEARED TO INFLUENCE INTESTINAL FLORA AS ASSESSED INDIRECTLY BY ANALYSIS OF TYPES OF NEUTRAL STEROLS ELIM WITH FECES.

Metabolism/MetabolitesDeoxycholic acid is not metabolized to any significant extent under normal conditions.
FDA Pharmacological Classification · 6 件

005990WHZZ

DEOXYCHOLIC ACID

関連反応

18 件
反応記録を作成
HRID 241529 の反応式
HRID 241529反応物として
HRID 258235 の反応式
HRID 258235反応物として
HRID 385172 の反応式
HRID 385172生成物として
HRID 463532 の反応式
HRID 463532反応物として
HRID 481936 の反応式
HRID 481936生成物として
HRID 586111 の反応式
HRID 586111反応物として
HRID 601753 の反応式
HRID 601753生成物として
HRID 1296194 の反応式
HRID 1296194生成物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
83-44-3
PubChem CID
222528
DTXSID
DTXSID0042662
ChEMBL
CHEMBL406393、CHEMBL453873
ChEBI
CHEBI:28834
UNII
005990WHZZ
EC Number
201-478-5
Nikkaji
J3.873C
Melting Point · 2 件

176-178 °C

171 - 174 °C

Optical RotationSPECIFIC OPTICAL ROTATION: +55 DEG (ALCOHOL) @ 20 °C/D
Physical Description · 2 件

Solid; [Merck Index] White powder; [MSDSonline]

Solid

物理化学的性質

融点
171 · 171-174 °C(lit.)
比旋光度
55 · 55 º (c=1, EtOH)
沸点
437.26 °C · 437.26°C (rough estimate)
比重(密度)
0.9985 · 0.9985 (rough estimate)
蒸気圧
0.004 Pa · 0.004Pa at 20℃
屈折率
1.446 · 1.4460 (estimate)
闪点
9 ℃ · 9℃
貯蔵温度
room temp
溶解性
0.24 g/L · 0.24g/L(15℃)
酸解離定数(Pka)
5.15 · 5.15(at 20℃)
外見
個体
色
ホワイトからオフホワイト
由来生物
ox bile
水溶解度
0.24 g/L · 0.24g/L(15℃)
Merck
14 · 14,2899
BRN
3219882 · 3219882
安定性
安定。可燃性。強力な酸化剤とは相容れない。
化粧品成分の機能
スキンコンディショニング保湿剤皮膚コンディショニング剤 - 保湿剤
InChIKey
KXGVEGMKQFWNSR-LLQZFEROSA-N
SMILES
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C
LogP
5.34 at · 5.34 at 22℃ and pH5.7
表面張力
54 mN/m · 54mN/m at 51.3mg/L and 20℃
CAS データベース
83 · 83-44-3(CAS DataBase Reference)
EPAの化学物質情報
-24 · Cholan-24-oic acid, 3,12-dihydroxy-, (3.alpha.,5.beta.,12.alpha.)- (83-44-3)

化学的性質

化学的特性white powder

毒性情報

Interactions · 3 件

...COMPETITION FOR EXTRAVASCULAR BINDING SITES BY DEOXYCHOLIC ACID MAY EXPLAIN REDUCED VOL OF DISTRIBUTION OF BROMSULFOPHTHALEIN IN PRESENCE OF BILE ACID.

COMPD INCL DEOXYCHOLATE POTENTIATED ANTISTAPHYLOCOCCI ACTIVITY OF GENTAMYCIN, MONOMYCIN, KANAMYCIN, & NEOMYCIN.

Deoxycholic acid was tested alone and as a promoter of N-nitrosobis(2-hydroxypropyl)amine induced carcinogenesis in the hamster. Three groups of 5 to 6-wk-old male Syrian hamsters (SYR)/NI were used and 10 animals per group were given subcutaneous injections of 0.9% NaCl, once per week for 5 weeks. Group 1 received no further treatment; groups 2 and 3 received 0.1% and 0.5% DCA in their feed for 30 weeks, respectively. Animals were autopsied at week 35. There was no significant difference in body wt. between groups 1 and 2, whereas there was a significant decrease in body weight for group 3 (P<0.005). There were no liver tumors, bile duct proliferation, gallbladder lesions or polyps, pancreatic lesions, or pancreatic duct hyperplasia in these 3 groups. In the promoter study, three groups of 5 to 6-wk-old hamsters (number not stated) were given a subcutaneous injection of 500 mg/kg body wt. N-nitrosobis(2-hydroxypropyl)amine per week for 5 weeks. Group 4 received no further treatment and the N-nitrosobis(2-hydroxypropyl)amine treatment was followed by 0.1% DCA (group 5) , or 0.5% DCA (group 6) in the feed for 30 weeks. There was a significant body weight loss (P<0.005) for groups 5 and 6 compared to group 4. DCA significantly increased the induction of cholangiocarcinomas 10/19 in group 5 (P<0.006); 9/25 in group 6 (P<0.05) compared to group 4 which had 1/15. Pancreatic carcinomas were significantly increased in group 5 (14/19, P<0.03). Therefore, under the conditions of this experiment, DCA was not carcinogenic when given alone but was an effective promoter of N-nitrosobis(2-hydroxypropyl)amine-induced hepatic and pancreatic carcinogenesis in hamsters.

Health EffectsChronically high levels of deoxycholic acid are associated with several forms of cancer including colon cancer.
Natural Pollution Sources · 2 件

DEOXYCHOLIC /ACID IS/...FORMED IN INTESTINE BY ACTION OF /ENTERIC/ BACTERIA ON SECRETED BILE ACIDS.

OCCURS IN BILE OF MAN, OX, SHEEP, DOG, GOAT & RABBIT.

Human Toxicity Excerpts · 2 件

Excess bile acids reaching the colon can reduce net water absorption and cause diarrhea. /Bile acids/

FOLLOWING IV INJECTION OF BILE SALTS...THERE IS MARKED FALL IN BLOOD PRESSURE ACCOMPANIED BY A BRADYCARDIA. ...JAUNDICE... IV, BILE SALTS CAUSE SKELETAL MUSCULAR HYPERACTIVITY, TWITCHING, SPASM, DECR IN THRESHOLD FOR NERVE IMPULSES. ...BILE ACIDS...CAUSE LYSIS OF RED & WHITE BLOOD CELLS. /BILE SALTS & BILE ACIDS/

Carcinogen ClassificationNot listed by IARC.
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Deoxycholic acid

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Non-Human Toxicity Excerpts · 5 件

IN DOGS, BILE SALTS DAMAGE GASTRIC MUCOSAL BARRIER, WHICH RESULTS IN BACK DIFFUSION OF ACID. ALTHOUGH NET DIFFUSION INTO LUMEN IS DIMINISHED, MUCOSAL CONCN IS INCREASED & ULCERATION OCCURS. /BILE SALTS/

DEOXYCHOLIC ACID ADDED TO CULTURES: WAS HIGHLY TOXIC TO RAT FIBROBLASTS & COLON CANCER CELLS, LESS TOXIC TO LIVER EPITHELIAL CELLS.

3 MMOL/L INSTILLED INTO RAT COLON LUMEN INCR PERMEABILITY TO WATER & TO UREA, MANNITOL & LACTOSE; DID NOT AFFECT OSMOTIC FILTRATION COEFFICIENTS.

CHOLIC ACID, TAUROCHOLIC ACID, GLYCOCHOLIC ACID, & DEOXYCHOLIC ACID EXERTED ANTIMICROBIAL ACTIVITY AGAINST STAPH IN VITRO: DEOXYCHOLATE MOST EFFECTIVE.

Although hepatocarcinogenesis has been reported to be promoted by exogenous administration of bile acids, the relation of endogenous bile acids to hepatocarcinogenesis is not completely understood. This study investigates the relationship between serum concentration of bile acids, the appearance of preneoplastic change, glutathione S-transferase placental form positive foci in the liver of male Donryu rats which had been fed 0.06% 3'-methyl-4-dimethylamino-azobenzene, and the effects of gomisin A, previously reported to inhibit the tumor promotion process. During the feeding of 3'-methyl-4-dimethylamino-azobenzene for 5 wks, the concn of serum bile acids were found to have increased significantly to several times the levels found at the start of the experiment. The increase of serum bile acids, especially deoxycholic acid, and the appearance of preneoplastic lesions, the number and area of glutathione S-transferase placental-positive foci in the liver, were significantly inhibited by simultaneous oral administration of gomisin A (30 mg/kg). When deoxycholic acid (100 mg/kg) was orally administered after an initiation by 3'-methyl-4-dimethylamino-azobenzene, serum bile acids and preneoplastic changes were significantly increased, these increases were inhibited by combined feeding of 0.03% gomisin A in the diet. There were good correlations between the serum concn of deoxycholic acid and the number of glutathione S-transferase placental-positive foci in the liver in both experimental protocols. These results confirm that deoxycholic acid is an endogenous risk factor for hepatocarcinogenesis and suggest that anti-promoter effect of gomisin A is based on improving metabolism of bile acids, including deoxycholic acid.

安全データ

wgk
3
tsca
TSCA listed
rtecs
FZ2100000
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
毒性
LD50 oral in rat: 1gm/kg
hs_code
29181990
risk_code
22-36/37/38-37-20/21/22
化審法
(9)-826
hazard_code
Xn
safety_code
26-36-37/39-22
Hazard Classifications
Acute Tox. 3 DermalAcute Tox. 3 InhalationAcute Tox. 3 OralFlam. Liq. 2STOT SE 1
ストレージクラス
3 - Flammable liquids
有毒物質データの
83-44-3(Hazardous Substances Data)

Established Pharmacologic Class [EPC] - Cytolytic Agent

Physiologic Effects [PE] - Decreased Cell Membrane Integrity

Deoxycholic acid is a Cytolytic Agent. The physiologic effect of deoxycholic acid is by means of Decreased Cell Membrane Integrity.

DEOXYCHOLIC ACID

MeSH Pharmacological ClassificationGastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic).
Absorption, Distribution and Excretion · 3 件

Deoxycholic acid is rapidly absorbed after subcutaneous administration. After maximum recommended single treatment dose, 100mg, the post-treatment plasma levels returned to endogenous levels within 24 hours. With the proposed treatment guideline, no accumulation is expected.

The exogenous deoxycholic acid joins the endogenous bile acid pool in the enterohepatic circulation and is excreted unchanged in feces along with endogenous deoxycholic acid.

LIVER NORMALLY SECRETES APPROX 24 G OF BILE SALTS IN 700 TO 1000 ML OF BILE IN 24 HR. MOST OF BILE SALTS ARE REABSORBED IN LOWER SMALL INTESTINE & AGAIN BECOME AVAILABLE FOR SECRETION. ... POOL OF BILE SALTS IS APPROX 2 TO 5 G. /BILE SALTS/

Tissue LocationsErythrocyte
Cellular LocationsExtracellular
Metabolite Pathways27-Hydroxylase Deficiency

用途と製造

Uses · 3 件

Naturally occurs in the bile of man, ox, sheep, dog, goat, and rabbit; [Merck Index] Used as emulsifying agent in food, a precursor in the synthesis of cortisone, and a gallbladder stimulant; [HSDB]

EMULSIFYING AGENT IN FOOD; PRECURSOR FOR ORG SYNTHESIS OF CORTISONE

CHOLERETIC

Methods of Manufacturing · 2 件

ISOLATION: WIELAND, SIEBERT, Z PHYSIOL CHEM 262, 1 (1939). FROM CHOLIC ACID: SIFFERD, US PATENT 2,765,316 (1956 TO ARMOUR). STRUCTURE & SYNTHESIS: LF LIESER, M FIESER, STEROIDS (REINHOLD, NY, 1959). LAB PREPN FROM OX BILE: GATTERMANN-WIELAND, PRAXIS DES ORGANISCHEN CHEMIKERS (DE GRUYTER, BERLIN, 40TH ED, 1961) PAGE 361.

Isolation from bile.

Formulations/PreparationsGRADES: TECHNICAL; FCC (AS DESOXYCHOLIC ACID)
General Manufacturing Information · 5 件

Cholan-24-oic acid, 3,12-dihydroxy-, (3.alpha.,5.beta.,12.alpha.)-: ACTIVE

COMPLEXES WITH FATTY ACIDS HAVE BEEN STUDIED EXTENSIVELY: SOBOTKA, GOLDBERG, BIOCHEM J 26, 555 (1932); SOBOTKA, CHEM REV 15, 362 (1934). SURFACE ACTIVITY: IDEM, CHEMISTRY OF THE STEROIDS, NY (1938).

BILE ACIDS DO NOT OCCUR IN BILE AS SUCH BUT RATHER AS THE SALT FORM CONJUGATED WITH TAURINE OR GLYCINE. /BILE ACIDS/

AN ADDUCT WITH MENTHOL IS MARKETED UNDER NAME DEGALOL.

FORMS MOLECULAR COORDINATION COMPD (SO CALLED CHOLEIC ACIDS) WITH MANY SUBSTANCES;

応用分野 · 6 件

解説コレイン酸,デオキシコール酸と種々の化合物との分子化合物の総称.とりわけステアリン酸,パルミチン酸,またはオレイン酸との分子化合物を狭義のコレイン酸とよぶ.デオキシコール酸と結合する成分をalcoholic componentとよび,脂肪酸およびそのエステル,アルコール,エーテル,炭化水素,アルカロイドがその成分となりうる.alcoholic componentの1分子に対して最高8分子のデオキシコール酸が結合し,分子化合物の安定性,溶媒に対する溶解性も種々に変化する.この性質を利用して,水に溶けやすいデオキシコール酸をコレイン酸にすることにより不溶性にすることができる.狭義のコレイン酸は,胆汁中に存在する.無色の結晶.水に不溶.アルコールまたは含水酢酸より再結晶できる.

用途デスオキシコーレート培地,XLD寒天培地などの調製、胆汁酸の研究用。光学分割剤。

説明Deoxycholic acid sodium salt, which is a secondary bile acid and the metabolite of intestinal bacteria, provides a nonsurgical treatment to significantly reduce submental fat in adults via injection directly into moderate-to-severe fatty tissue below the neck. When injected into fatty tissue, deoxycholic acid helps destroy fat cells. Although deoxycholic acid has many applications beyond human health, the application as a dyslipidemia drug was licensed to Kythera from Los Angeles Biomedical Institute at Harbor-UCLA Medical Center in 2007. Allergan acquired Kythera recently in 2015.

使用Deoxycholic acid has been used in a modified procedure to recover 40-80% of a protein from a 1 μg/mL solution. It forms complexes with fatty acid. Used as an emulsifying agent in food, a precursor in the synthesis of cortisone, and a gallbladder stimulant. It has been used to study assess how physiological concentrations of ursodeoxycholic acid (UDCA) vs. deoxycholic acid (DCA) affect barrier function in mouse intestinal tissue. Deoxycholic acid has been used in a study to assess a pH-Responsive Mechanism of a Deoxycholic Acid and Folate Co-Modified Chitosan Micelle under Cancerous Environment. It has also been used in a study to investigate dose-dependent anti-inflammatory effect of ursodeoxycholic acid in experimental colitis.

一般的な説明This [TM="Certified Spiking Solution" is suitable for use as starting material in the preparation of linearity standards, calibrators, and controls in LC-MS/MS and GC/MS bile acid testing methods. Deoxycholic acid (DCA), also known as deoxycholate and cholanoic acid is a secondary bile acid that aids in the absorption of fats in the intestine. Mass spectrometry-based analysis of DCA is routinely performed in clinical diagnostic testing applications including neonatal testing of inborn errors of bile acid synthesis and differentiating among types of familial intrahepatic cholestasis.

使用用途デオキシコール酸単体では、デスオキシコーレート培地やXLD寒天培地などの調製、胆汁酸の研究、および光学分割剤として利用されています。また、葉酸と共修飾したキトサンミセルの癌化環境下において、pH応答性メカニズムを評価する研究用途もあります。 デオキシコール酸と脂肪酸との複合体は、食品の乳化剤、コルチゾン合成の、利胆剤として使用可能です。医薬品分野では、ウルソデオキシコール酸は胃腸薬として、ケノデオキシコール酸はコレステロール系胆石溶解の薬物療法や胃腸薬に用いられています。

調製方法 · 2 件

製造方法デオキシコール酸は、天然に存在する胆汁酸で、主に家畜の胆嚢や牛の胆汁から抽出されます。しかし、天然の胆汁酸を抽出する方法は効率が低く、コストがかかるため、工業的には、現在は、主に化学合成によって製造されています。 デオキシコール酸の合成の第一段階は、ケノデオキシコール酸 (CDCA) の合成です。ケノデオキシコール酸は胆汁酸の1種で、デオキシコール酸の前駆体です。ケノデオキシコール酸はコレステロールを原料とした酸化反応によって合成されます。

純化方法Reflux the acid with CCl4 (50mL/g), filter, evaporate under vacuum at 25o, recrystallise the residue from acetone and dry it under vacuum at 155o [Trenner et al. J Am Chem Soc 76 1196 1954]. A solution of (cholic acid-free) material (100mL) in 500mL of hot EtOH is filtered, evaporate it to less than 500mL on a hot plate, and pour it into 1500mL of cold diethyl ether. The precipitate, filtered off by suction, is crystallised twice from 1-2 parts of absolute EtOH, to give an alcoholate, m 118-120o, which is dissolved in EtOH (100mL for 60g) and poured into boiling water. After boiling until free of the EtOH, the precipitate is filtered off, dried, ground and dried to constant weight in vacuo [Sobotka & Goldberg Biochem J 26 555 1932]. Deoxycholic acid is also freed from fatty acids and cholic acid by silica gel chromatography and elution with 0.5% acetic acid in ethyl acetate [Tang et al. J Am Chem Soc 107 4058 1985]. It can also be recrystallised from butanone. Its solubility in H2O at 15o is 0.24g/L, but in EtOH it is 22.07g/L. [Beilstein 10 IV 1608.]

上流・下流製品情報

下流製品

2-[(3α,12α-ジヒドロキシ-24-オキソ-5β-コラン)-24-イルアミノ]エタンスルホン酸ナトリウムN-(3α,12α-ジヒドロキシ-24-オキソ-5β-コラン-24-イル)グリシンデオキシコール酸ナトリウム